This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the delivery of Bydureon BCISE, a 2 mg autoinjector medication used to treat diabetes. The firm-fixed-price delivery order, valued at $3,413.35, has a completion date of November 15, 2024. No set-aside requirements were used for this award.
The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies, including the Department of Justice Federal Bureau of Investigation through a separate IDC valued at $750,000.
Generated 2/13/25, 9:19 AM